2 High-Yielding Dividend Stocks to Buy for Passive Income in April

Pfizer’s 6.4% forward yield is presented as sustainable, supported by a deep pipeline, with newer products like Abrysvo generating about $1B in sales last year and Elrexfio reaching $304M. Medical Properties Trust is also described as recovering after tenant defaults, dividend cuts, and asset sales, and now offers a 7% forward yield that management recently increased. The article is constructive on both names for long-term income investors, though it is opinion-driven rather than a fresh catalyst.

Analysis

The market is underwriting these as yield names, but the more interesting angle is optionality. In both cases, the current dividend is functioning as a sentiment floor: it narrows downside, but the real upside comes from the market re-rating durability once balance-sheet pressure and asset quality concerns fade. That matters because income buyers tend to arrive late; the better trade is often to own them before the yield crowd gets comfortable.

For PFE, the underappreciated factor is pipeline pacing, not just pipeline depth. A few visible approvals in the next 12-24 months can offset patent cliffs enough to stabilize earnings, but the stock likely won’t fully respond until investors see a cleaner bridge from legacy revenue to late-stage assets. The risk is that the market stays in “show me” mode longer than bulls expect, which keeps multiple expansion capped even if fundamentals stop deteriorating.

MPW is a different setup: the story is less about turnaround purity and more about the market overpricing tenant contagion risk after the prior defaults. If lease coverage normalizes and capital allocation remains disciplined, the stock can grind higher over several quarters simply because the bar is low and the dividend reset has already washed out many forced sellers. The main tail risk is not another idiosyncratic tenant event, but a higher-for-longer rate backdrop that keeps refinancing spreads wide and delays any full de-risking of the equity.

Relative value favors owning the names only if you are being paid for the patience. PFE offers cleaner quality and a longer-dated catalyst path; MPW offers a higher beta rebound if operating stability persists. The consensus is probably underestimating how much of the negative narrative is already embedded, but also overestimating the speed of rerating—these are 6-18 month trades, not quick reversals.

Key Decisions for Investors

• Long PFE for a 6-12 month horizon ahead of late-stage pipeline readouts; target a rerating as dividend durability + product growth reduce the market’s 'value trap' discount. Add on weakness if the stock sells off after generic/patent-loss headlines.
• Long MPW selectively only after confirming tenant normalization and refinancing access; this is a 9-18 month recovery trade with asymmetric upside if the market stops pricing bankruptcy contagion into every asset.
• Pair trade: long PFE / short a higher-priced defensives basket with weaker balance-sheet quality; PFE has better downside support from yield, but more upside if pipeline visibility improves.
• Avoid chasing both names after sharp yield-driven rallies; the near-term move is likely to be mean-reverting unless there is a fresh catalyst from guidance, approvals, or asset-sale execution.